Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May:161:103325.
doi: 10.1016/j.critrevonc.2021.103325. Epub 2021 Apr 6.

Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications

Affiliations
Review

Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications

Irene Paraboschi et al. Crit Rev Oncol Hematol. 2021 May.

Abstract

Near-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g. a monoclonal antibody, moAb). Delivery of a conjugate in vivo leads to accumulation at the tumour cell surface by binding to cell surface receptors or antigens. Upon deployment of focal NIR-light, irradiation of the conjugate results in a rapid, targeted cell death. However, the mechanisms of action to produce the cytotoxic effects have yet to be fully understood. Herein, we bring together the current knowledge of NIR-PIT from preclinical and clinical studies in a variety of cancers highlighting the key unanswered research questions. Furthermore, we discuss how to enhance the local control of solid cancers using this novel treatment regimen.

Keywords: Clinical trials; In vitro; In vivo; Local control; Monoclonal antibodies; Near-InfraRed fluorophores; PhotoImmunoTherapy; Solid cancers.

PubMed Disclaimer

Conflict of interest statement

Nothing to declare.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Direct cytotoxic effects of NIR-PIT on tumour cells expressing cancer specific antigens. 1A) Upon NIR-light irradiation, the IR700 dye changes shape and solubility, becoming hydrophobic and showing a tendency to aggregate. This APC physical modification significantly stress the cell membrane with a consequent disruption of its transmembrane osmotic gradient. 1B) The following disruption of the transmembrane osmotic gradient leads to cell swelling, blebbing and bursting. The release of intracytoplasmatic antigens and Damage-Associated Molecular Patterns (DAMPs) in the extracellular space activates the host immune system against the dying tumour cells. The overall process has been named Immunogenic Cell Death (ICD).
Fig. 2
Fig. 2
In vitro morphological changes following affibody-based PIT. Incubation of U87-MGvIII spheroids with the ZEGFR:03115–IR700DX for 6 h and irradiation with a red LED (16 J/cm2) induced phototoxic cell death and disintegration of the architectural structure of the spheroid population (Courtesy of Dr Gabriela Kramer-Marek) (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
Fig. 3
Fig. 3
Cytotoxic effects of NIR-PIT induced by the activation of the host anti-cancer immune response. Following the exposure to NIR light, dying tumour cells rapidly release cancer-specific antigens and membrane damage danger signals which promote the maturation of Dendritic Cells. The consequent activation of tumour infiltrating CD8 + T cells result in the selective killing of residual tumour cells.

Similar articles

Cited by

References

    1. Amos S.M., Duong C.P.M., Westwood J.A. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;118(3):499–509. doi: 10.1182/blood-2011-01-325266. - DOI - PubMed
    1. Anderson E.D., Gorka A.P., Schnermann M.J. Near-infrared uncaging or photosensitizing dictated by oxygen tension. Nat. Commun. 2016;7:13378. doi: 10.1038/ncomms13378. - DOI - PMC - PubMed
    1. Anderson E.D., Sova S., Ivanic J., Kelly L., Schnermann M.J. Defining the conditional basis of silicon phthalocyanine near-IR ligand exchange. Phys. Chem. Chem. Phys. PCCP. 2018;20(28):19030–19036. doi: 10.1039/c8cp03842b. - DOI - PMC - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Burger M., Catto J.W.F., Dalbagni G. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 2013;63(2):234–241. doi: 10.1016/j.eururo.2012.07.033. - DOI - PubMed

LinkOut - more resources